Revista Colombiana de Reumatología (English Edition)最新文献

{"title":"Comparison of the classification criteria for antiphospholipid syndrome (APS) of ACR/EULAR 2023 vs. Sidney criteria 2006 in a sample of pregnant women with APS","authors":"Laura Vela Valle ,&nbsp;Jorge Perbech Larraz ,&nbsp;Margarita Míriam Lesta Colmenero ,&nbsp;Maria Patricia Solana Hidalgo ,&nbsp;Borja del Carmelo Gracia Tello ,&nbsp;Mercedes Pilar Pérez Conesa ,&nbsp;Luis Sáez Comet","doi":"10.1016/j.rcreue.2026.102189","DOIUrl":"10.1016/j.rcreue.2026.102189","url":null,"abstract":"<div><h3>Introduction</h3><div>Antiphospholipid antibody syndrome (APS) is characterized by the presence of thrombosis and obstetric pathology.</div></div><div><h3>Objective</h3><div>To analyze the diagnostic validity of the APS classification criteria published in 2023 by the American College of Rheumatology (ACR) together with the European Alliance of Associations for Rheumatology (EULAR) and to compare them with the 2006 Sydney criteria in pregnant women with suspected APS.</div></div><div><h3>Material and methods</h3><div>Retrospective observational cohort study based on the follow-up of 754 pregnancies by the Autoimmune Diseases Unit of the Miguel Servet University Hospital in Zaragoza. The diagnosis of its specialist doctors was considered to be gold-standard. Sensitivity, specificity, positive and negative predictive values, and area under the curve (AUC) were calculated for the Sydney and ACR/ELAR criteria, with a value of <em>P</em> &lt; .05.</div></div><div><h3>Results</h3><div>The 2023 ACR/EULAR classification criteria had a sensitivity of 17.47% (AUC 0.583) compared to 74.70% (AUC 0.871) for the Sydney criteria.</div></div><div><h3>Discussion</h3><div>The new ACR/EULAR 2023 criteria are more complex due to the incorporation of new evidence in antiphospholipid syndrome; However, in terms of results, we found a clearly lower sensitivity in the new criteria in agreement with the findings of other studies.</div></div><div><h3>Conclusions</h3><div>The diagnosis of APS continues to be a challenge, due to its multifactorial nature, high prevalence of thrombosis and pregnancy morbidity in the population, broad range of antiphospholipid antibody and the absence of a gold-standard. The results of our study suggest a worse diagnostic performance of the ACR/EULAR criteria compared to the Sydney criteria for the classification of obstetric APS, so further studies are needed to confirm these findings.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"33 1","pages":"Article 102189"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147453987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arthritis mutilans, not always psoriatic disease. Case report","authors":"Natalia Andrea Uribe-Ruiz ,&nbsp;Santiago José Morón-Serrano ,&nbsp;Gloria Vásquez ,&nbsp;Luis Alonso González-Naranjo ,&nbsp;Carlos Horacio Muñoz-Vahos ,&nbsp;Adriana Lucía Vanegas-García","doi":"10.1016/j.rcreue.2025.102166","DOIUrl":"10.1016/j.rcreue.2025.102166","url":null,"abstract":"<div><h3>Introduction</h3><div>Arthritis mutilans is described in psoriatic arthropathy and as a rare manifestation of systemic sclerosis, but not in overlap syndromes.</div></div><div><h3>Findings and diagnosis</h3><div>We describe the case of a patient with a systemic sclerosis/systemic lupus erythematosus overlap syndrome who initially had non-erosive polyarthritis and progressed to arthritis mutilans requiring immunosuppressive therapy change.</div></div><div><h3>Conclusion</h3><div>Recognition of this complication is essential because of the treatment and prognostic implications.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"33 1","pages":"Article 102166"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147453992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of rhupus treated with filgotinib: A promising therapeutic perspective","authors":"Raffaele Barile ,&nbsp;Cinzia Rotondo ,&nbsp;Valeria Rella ,&nbsp;Francesco Paolo Cantatore ,&nbsp;Addolorata Corrado","doi":"10.1016/j.rcreue.2026.102180","DOIUrl":"10.1016/j.rcreue.2026.102180","url":null,"abstract":"<div><h3>Rhupus syndrome</h3><div>Rhupus syndrome, characterized by overlapping clinical features of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), presents significant therapeutic challenges due to its complex pathogenesis and limited treatment options. This case report evaluates the efficacy of filgotinib, a selective JAK1 inhibitor, in a patient with refractory rhupus syndrome.</div></div><div><h3>Case presentation</h3><div>A 42-year-old male, initially diagnosed with SLE in 2013, presented with persistent polyarthritis, cutaneous manifestations, and constitutional symptoms. Conventional treatments including hydroxychloroquine, methotrexate, and belimumab failed to achieve adequate disease control.</div></div><div><h3>Diagnosis and treatment</h3><div>In October 2022, the diagnosis was revised to rhupus based on the evolution of clinical manifestations and laboratory findings, leading to the initiation of filgotinib, a JAK1 inhibitor. Disease activity was monitored over 24 months using standardized assessment tools.</div></div><div><h3>Results</h3><div>Significant clinical improvement was observed within weeks of filgotinib initiation, enabling prednisone dose reduction and maintaining low disease activity throughout the 24-month follow-up period.</div></div><div><h3>Conclusion</h3><div>This case highlights the therapeutic potential of filgotinib in managing rhupus syndrome but further research and larger clinical trials are necessary to establish filgotinib's therapeutic potential and safety profile in the management of SLE.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"33 1","pages":"Article 102180"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147453959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease relapse in idiopathic inflammatory myopathies: A 10-year registry-based follow-up multicentre study in Colombia","authors":"Pablo Arango Guerra ,&nbsp;Alejandro Echavarría Cross ,&nbsp;Manuel Alejandro Giraldo Delgado ,&nbsp;Mauricio Murillo Moreno ,&nbsp;María Pérez-Restrepo ,&nbsp;Juan Camilo Díaz-Coronado ,&nbsp;Diego Fernando Rojas-Gualdrón ,&nbsp;Neil Pertuz","doi":"10.1016/j.rcreue.2025.102162","DOIUrl":"10.1016/j.rcreue.2025.102162","url":null,"abstract":"<div><h3>Introduction</h3><div>Disease relapses of idiopathic inflammatory myopathies (IIM) play a significant role in the burden of disease. However, Colombian studies with long-term follow-ups are scarce.</div></div><div><h3>Objective</h3><div>To estimate the ten-year relapse-free survival in patients with idiopathic inflammatory myopathy treated at a specialized medical center for autoimmune diseases with presence in different cities in Colombia.</div></div><div><h3>Method</h3><div>This is a retrospective follow-up study based on medical records. All patients diagnosed with idiopathic inflammatory myopathy treated between January 2012 and June 2022 were included. The time to relapse was defined as the outcome variable. Additionally, demographic, clinical, laboratory, and treatment variables were characterized. Analyses were performed using Weibull survival regression for interval-censored data.</div></div><div><h3>Results</h3><div>A total of 278 patients followed for a mean of 6.60 years were included. Of these, 70.9% were women, with a median age of 57 (IQR 40–66) years. Dermatomyositis (60.1%) and polymyositis (28.1%) were the most frequent phenotypes. Relapse-free survival at one year was 86.3%, and at five years, 68.3%, with a median relapse-free time of 13.8 years. By phenotype, the lowest median relapse-free survival rates were observed for antisynthetase syndrome at 3 years, immune-mediated necrotizing myopathy at 6 years, and juvenile dermatomyositis at 7.3 years.</div></div><div><h3>Conclusion</h3><div>Relapse-free survival is highly heterogeneous according to the clinical phenotype of idiopathic inflammatory myopathy, being lowest in patients with antisynthetase syndrome.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"33 1","pages":"Article 102162"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147453986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Profile of use and cost of care in knee osteoarthritis","authors":"Erick Baltazar Pano Nogueda ,&nbsp;Enrique Villarreal Ríos ,&nbsp;Liliana Galicia Rodríguez ,&nbsp;Mireya Franco Saldaña ,&nbsp;Mariana Del Rayo Guerrero Mancera ,&nbsp;Laura Alicia Cu Flores","doi":"10.1016/j.rcreue.2025.102158","DOIUrl":"10.1016/j.rcreue.2025.102158","url":null,"abstract":"<div><h3>Introduction</h3><div>The profile of health service use in the care of knee osteoarthritis determines the cost of care.</div></div><div><h3>Objective</h3><div>To determine the profile of use and cost of care in knee osteoarthritis.</div></div><div><h3>Materials and methods</h3><div>Study of health service profile of use and cost, 258 clinical records were studied. The profile of use identified the type and number of services used in 1 year. The average annual cost was determined by identifying the fixed unit cost, estimated using the time and motion technique, and the variable unit cost, identified using the micro-costing technique, the sum of both resulted in the average unit cost and was multiplied by the profile of use to identify the average annual cost. With this result, projections were made adopting assumptions for specific populations.</div></div><div><h3>Results</h3><div>The average annual cost of knee osteoarthrosis care was USD $ 205.82; the highest cost corresponds to the fixed cost of consultation and hospitalization services. The total projected cost for 6408 patients with osteoarthritis is USD $ 1,318,917 and for 4644 patients with osteoarthrosis is USD $ 955,844,529.</div></div><div><h3>Conclusion</h3><div>The cost of care for knee osteoarthritis is high, the projections for the average cost of care for knee osteoarthritis are worrying, this scenario will be true as long as the adopted assumptions are met.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"33 1","pages":"Article 102158"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147454074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of osteoporosis in patients with ankylosing spondylitis: systematic review, and meta-analysis","authors":"Pedro Arbey Quevedo Mayorga ,&nbsp;Andrés Alfonso González ,&nbsp;Javier Mauricio Mora Méndez ,&nbsp;Juan Carlos Vela Quevedo ,&nbsp;Lilian Marcela Estupiñán Moya ,&nbsp;Angelica María Quintero ,&nbsp;Carlos Eduardo García Morón ,&nbsp;César Augusto Cantillo Moreno","doi":"10.1016/j.rcreue.2026.102175","DOIUrl":"10.1016/j.rcreue.2026.102175","url":null,"abstract":"<div><h3>Introduction</h3><div>The variability in the identification of osteopenia and osteoporosis in AS (ankylosing spondylitis) is related to the possible overestimation of BMD (bone mineral density) identified by DXA (dual x-ray absorptiometry) in the lumbar spine (LS) and femoral neck (FN) due to changes in bone neoformation in the anterior vertebral ligament and enthesis, which leads to the under-identification of alterations in the BMD of this group of patients. This justifies evaluating different BMD estimation techniques such as QCT (quantitative dual-energy tomography) to optimize the identification of this complication. Our objective was to evaluate the available evidence regarding the identification of osteoporosis and osteopenia through DXA versus QCT techniques in patients with AS.</div></div><div><h3>Methodology</h3><div>A systematic review and meta-analysis were carried out following the PRISMA-P checklist 2015 methodology. The databases consulted were MEDLINE CENTRAL (Cochrane Central Register of Controlled Trials), EMBASE, LILACS, GOOGLE SCHOLAR, SCIELO from 2010 to December 2021; we included randomized clinical trials, cohort studies, cases and controls, as well as cross-sectional studies in PROSPERO (CRD42023472431) on both methods. The effect was estimated from fixed or random effects models according to the estimation of heterogeneity by I².</div></div><div><h3>Results</h3><div>The search yielded 287 studies, of which only 3 were included. There were 109 patients in total, the mean age was 49.5±4.8, a greater probability of OP was evident (RR = 1.91 95% CI .65–5.62 p = .23) and osteopenia (RR = 1.44 95% CI = .86–2.42 p = .16) with QCT vs. DXA, without statistical significance. The difference in means in the bone density was significant between the two techniques, being lower in QCT (MD = −833 Z = −8.38 p = .001).</div></div><div><h3>Conclusions</h3><div>QCT is a useful technique in determining BMD in these patients, but the available evidence is still insufficient to conclude which is the least effective technique for diagnosing OP in AS.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"33 1","pages":"Article 102175"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147453990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond expectations: Concurrent presence of beta thalassemia and Sjögren's syndrome","authors":"Mateo Aguirre Flórez ,&nbsp;Daniel Toro Restrepo ,&nbsp;Lina María Saldarriaga Rivera ,&nbsp;Henry Idrobo Quintero ,&nbsp;Laura Alejandra Jiménez Osorio ,&nbsp;Valeria López Pulgarín ,&nbsp;Daniel Millán Morales","doi":"10.1016/j.rcreue.2026.102168","DOIUrl":"10.1016/j.rcreue.2026.102168","url":null,"abstract":"<div><h3>Background</h3><div>Beta thalassaemia and Sjögren's syndrome are rare diseases with distinct aetiologies. Beta thalassaemia is an inherited haemoglobinopathy that causes chronic anemia, while Sjögren's syndrome is an autoimmune disease that affects exocrine glands.</div></div><div><h3>Case report</h3><div>We present a 45-year-old female with beta-thalassaemia diagnosed by genetic testing who developed Sjögren's syndrome symptoms. The diagnosis was confirmed by clinical, serological, and histopathological criteria. This is the first documented case in a Colombian tertiary institution.</div></div><div><h3>Conclusions</h3><div>Beta-thalassaemia and Sjögren's syndrome coexistence is extremely rare, highlighting the need for a multidisciplinary diagnostic approach. Further investigation into possible molecular and genetic links is needed.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"33 1","pages":"Article 102168"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147453995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular risk factors related to arterial stiffness in patients with rheumatoid arthritis in low disease activity","authors":"Gabriel-Santiago Rodríguez-Vargas ,&nbsp;Jaime-Andrés Rubio-Rubio ,&nbsp;Pedro Santos-Moreno ,&nbsp;Darío Echeverri ,&nbsp;Luz-Dary Gutiérrez-Castañeda ,&nbsp;Paula-Katherine Bautista-Niño ,&nbsp;Adriana Rojas-Villarraga","doi":"10.1016/j.rcreue.2025.102146","DOIUrl":"10.1016/j.rcreue.2025.102146","url":null,"abstract":"<div><h3>Introduction</h3><div>Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease associated with the chronic inflammatory state.</div></div><div><h3>Objective</h3><div>The objective was to describe arterial stiffness in RA patients with low disease activity and its relationship with cardiovascular risk factors.</div></div><div><h3>Materials and methods</h3><div>Case series study. Consecutive inclusion of patients with RA in low disease activity. Sociodemographic, clinical and laboratory data, and disease activity score-28 were captured. Arterial stiffness [pulse wave velocity (PWV), oscillometric method] was assessed. Univariate and bivariate analyses, correlations (Rho Spearman), and principal component analysis.</div></div><div><h3>Results</h3><div>52 patients (76.9% women) were included. Median age 57 years (interquartile range-IQR 9). Median disease activity score-28 (DAS28) 2.6 (IQR-1.3), low activity. Mean PWV 8.45 (Standard deviation 3.1) m/sec. PWV in patients treated with methotrexate was lower (<em>p</em> = .013). Age was correlated with PWV (<em>p</em> = .006). Aortic augmentation index was higher in women (<em>p</em> = .015) and in patients with familial autoimmunity (<em>p</em> = .05). Framingham cardiovascular risk score correlated with pulse pressures. The number of cups of coffee consumed was correlated (inversely) with the aortic augmentation index (<em>p</em> = .042). Principal component analysis (4 components) explained 70.1% of the variance.</div></div><div><h3>Conclusions</h3><div>PWV levels in patients with RA in low disease activity were similar to those reported in the population without RA. Despite not being elevated, they correlate with traditional and non-traditional cardiovascular risk factors (methotrexate, familial autoimmunity, coffee consumption).</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"33 1","pages":"Article 102146"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147454082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life of patients with fibromyalgia presenting headache and/or depressive symptoms","authors":"Yasmine Fortes ,&nbsp;Wallyson Souza ,&nbsp;Adriana Soares ,&nbsp;Maria das Graças Sousa ,&nbsp;Bruna Castro ,&nbsp;Raimundo Silva-Néto ,&nbsp;Gabriela Uchôa","doi":"10.1016/j.rcreue.2026.102152","DOIUrl":"10.1016/j.rcreue.2026.102152","url":null,"abstract":"<div><h3>Introduction</h3><div>Fibromyalgia has a high degree of co-occurrence with a number of conditions. The association of fibromyalgia, headache and mood disorders is well observed.</div></div><div><h3>Objective</h3><div>To analyze the relationship between these manifestations, exploring whether the quality of life in patients with fibromyalgia is influenced by the presence of depressive symptoms and chronification of headache.</div></div><div><h3>Materials and methods</h3><div>A retrospective observational cross-sectional study was carried out to determine the quality of life of patients with fibromyalgia presenting with headache and/or depressive symptoms. The samples were evaluated using the Widespread Pain Index (WPI) and Symptom Severity (SS) questionnaires to confirm the diagnosis of fibromyalgia. Quality of life and level of depressive symptoms were assessed, respectively, by the Fibromyalgia Impact Questionnaire (FIQ) and the Patient Health Questionnaire-9 (PHQ-9).</div></div><div><h3>Results</h3><div>A total of 120 patients (3 men and 117 women) diagnosed with fibromyalgia were interviewed, with ages ranging from 23 to 65 years. The most common primary headache was chronic migraine (45%). While depressive symptoms was observed in 118 patients (98.33%). The factors degree of depressive symptoms and headache chronicity were marginally significant in explaining the quality of life of patients with fibromyalgia.</div></div><div><h3>Conclusions</h3><div>Faced with a disease with such a possibility of being associated with other complex conditions, multidisciplinary monitoring becomes a preponderant factor in the treatment of the entire patient.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"33 1","pages":"Article 102152"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147454080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-TIF1γ-positive dermatomyositis with interstitial lung involvement: Report of two cases","authors":"Pablo Arango Guerra ,&nbsp;Santiago Monsalve Yepes ,&nbsp;Andrés Chavarriaga Restrepo ,&nbsp;Carlos Jaime Velásquez","doi":"10.1016/j.rcreue.2025.06.012","DOIUrl":"10.1016/j.rcreue.2025.06.012","url":null,"abstract":"<div><h3>Introduction</h3><div>The association of certain myositis-specific antibodies (MSA) with the development of interstitial lung disease (ILD) in relation to inflammatory myopathies, such as antisynthetase syndrome and anti-MDA5, is well known. However, the potential relationship with the anti-TIF1γ antibody is not well understood, as the reported cases to date are few and have not allowed for solid confirmation of this association. Most of the literature has focused primarily on the association with malignant neoplasms. We aim to include two new cases in the existing literature to support the assertion of the link despite its infrequency.</div></div><div><h3>Objective</h3><div>To report two cases of ILD associated with anti-TIF1γ positive dermatomyositis (DM).</div></div><div><h3>Materials and methods</h3><div>A description of the clinical characteristics of two cases of anti-TIF1γ positive DM with ILD and a comparison with analogous cases.</div></div><div><h3>Results</h3><div>Two cases are described, the first of a 47-year-old man and the second of a 57-year-old woman, both diagnosed with anti-TIF1γ positive DM with the presence of ILD. Underlying malignancy was ruled out due to the presence of the MSA in question, and other potential causes of ILD were excluded, leading to the initiation of immunosuppressive treatment in both cases.</div></div><div><h3>Conclusion</h3><div>It is essential to further investigate the relationship between inflammatory myopathy and how different MSAs, other than antisynthetase and anti-MDA5 are also associated with ILD. Finding two cases related to anti-TIF1γ and knowing that there are analogous cases generates this hypothesis.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 4","pages":"Pages 409-415"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145335250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}